GLPwatch
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
Ann Intern Med · 2024
Last updated 2026-08-28| Journal | Ann Intern Med, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.10 |
| NIH percentile | 8 |
| Molecules | semaglutide |
Abstract
Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. N Engl J Med. 2024;391:109-121. 38785209.
Verbatim abstract via PubMed 39222509 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.